Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionPanagora Asset Management Inc
Latest Disclosed Ownership10,343 shares
Latest Disclosed Value $ 3,422,188
Panagora Asset Management Inc reports 66.47% decrease in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 14, 2026 - Panagora Asset Management Inc filed a 13F-HR form disclosing ownership of 10,343 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $2,954,995 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 30,843 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -66.47% during the quarter. The current value of the position is $2,694,352 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,343 -20,500 -66.47 3,422 -72.10 0.0128
2026-02-13 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 30,843 -31,511 -50.54 12,265 -56.87 0.0435
2025-11-13 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 62,354 -30,145 -32.59 28,433 -5.73 0.1146
2025-08-13 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 92,499 -4,305 -4.45 30,163 15.39 0.1359
2025-05-15 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 96,804 41,340 74.53 26,139 100.28 0.1306
2025-02-13 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 55,464 -70,427 -55.94 13,051 -62.31 0.0603
2024-11-13 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 125,891 106,081 535.49 34,624 619.36 0.1654
2024-07-29 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 19,810 12,353 165.66 4,814 332.05 0.0242
2024-05-07 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,457 0 0.00 1,114 -21.93 0.0058
2024-02-08 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,457 0 0.00 1,427 8.11 0.0080
2023-10-31 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,457 2,336 45.62 1,321 35.80 0.0082
2023-08-11 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,121 0 0.00 973 -5.17 0.0057
2023-05-12 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,121 -152 -2.88 1,026 -18.20 0.0065
2023-02-13 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,273 -1,079 -16.99 1,253 -1.42 0.0082
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,352 -213 -3.24 1,271 32.67 0.0088
2022-08-15 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,565 0 0.00 958 -10.63 0.0063
2022-05-12 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,565 3,223 96.44 1,072 89.07 0.0058
2022-02-10 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,342 -2,667 -44.38 567 -50.04 0.0030
2021-11-10 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,009 0 0.00 1,135 11.38 0.0061
2021-08-11 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,009 -411 -6.40 1,019 12.47 0.0055
2021-05-12 2021-03-31 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 6,420 1,446 29.07 906 40.25 0.0051
2021-02-10 2020-12-31 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 4,974 1,322 36.20 646 21.43 0.0038
2020-11-13 2020-09-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 3,652 0 0.00 532 -1.66 0.0033
2020-08-12 2020-06-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 3,652 144 4.10 541 41.62 0.0034
2020-05-14 2020-03-31 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 3,508 0 0.00 382 -5.45 0.0027
2020-02-12 2019-12-31 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 3,508 257 7.91 404 54.79 0.0018
2019-11-12 2019-09-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 3,251 -699 -17.70 261 -9.06 0.0012
2019-08-09 2019-06-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 3,950 0 0.00 287 -22.22 0.0013
2019-05-15 2019-03-31 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 3,950 -728 -15.56 369 8.21 0.0016
2019-02-14 2018-12-31 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 4,678 584 14.26 341 -4.75 0.0016
2018-11-13 2018-09-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 4,094 979 31.43 358 16.61 0.0013
2018-08-14 2018-06-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 3,115 371 13.52 307 -6.12 0.0012
2018-05-15 2018-03-31 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 2,744 19 0.70 327 -5.49 0.0013
2018-02-14 2017-12-31 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 2,725 0 0.00 346 8.13 0.0013
2017-11-14 2017-09-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 2,725 -1,607 -37.10 320 -7.51 0.0013
2017-08-14 2017-06-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 4,332 1,350 45.27 346 126.14 0.0014
2017-05-15 2017-03-31 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 2,982 0 0.00 153 36.61 0.0006
2017-02-14 2016-12-31 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 2,982 0 0.00 112 -44.55 0.0005
2016-11-14 2016-09-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 2,982 -953 -24.22 202 -7.34 0.0010
2016-08-15 2016-06-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 3,935 -345 -8.06 218 -18.96 0.0011
2016-05-16 2016-03-31 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 4,280 972 29.38 269 -13.50 0.0013
2016-02-12 2015-12-31 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 3,308 -1,179 -26.28 311 -13.85 0.0015
2015-11-13 2015-09-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 4,487 4,487 0.00 361 0.0019
2014-11-12 2014-09-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 0 -677 -100.00 0 -100.00
2014-08-14 2014-06-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 677 0 0.00 43 -4.44 0.0002
2014-05-15 2014-03-31 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 677 -232 -25.52 45 -22.41 0.0002
2014-02-21 2013-12-31 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 909 0 0.00 58 0.00 0.0003
2013-11-14 2013-09-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 909 909 58 0.0003
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.